Background: Kaposi sarcoma (KS) is a human herpesvirus-8-associated vascular malignancy with four subtypes. Although several local therapies are available for cutaneous lesions, no standard treatment exists. Laser therapy is a minimally invasive treatment option; however, its efficacy and safety remain unclear. Objectives: To systematically review and analyze the available literature on the efficacy and safety of laser-based treatment protocols for cutaneous KS lesions. Methods: A comprehensive literature search was conducted up to August 2025 to identify randomized controlled trials, observational studies, and case series with ≥3 patients who received laser therapy for cutaneous KS. Data on patient and disease characteristics, laser protocols, outcomes and adverse events were extracted from the included studies. Results: Eight studies involving 79 patients with 371 treated lesions were included in this systematic review. The reported outcome rates varied greatly between different modalities, with inconsistent outcome definitions. No recurrence was reported in seven studies, whereas the condition in all cases in the eighth study recurred. Overall, laser therapy was well tolerated with minimal adverse effects, including mild atrophic scarring, transient post-inflammatory changes, and hyperpigmentation. Six studies were eligible for meta-analysis, yielding a pooled significant response rate of 88% (95% CI: 44.1–98.6%, I2 = 86.3%). Conclusions: Available data indicate that laser therapy may represent a safe and effective option for cutaneous KS, particularly Nd:YAG, which demonstrated good efficacy with low recurrence rates; however, further research is required to define its efficacy more precisely and to standardize treatment protocols.
17 September 2026 in Journal of Cosmetic Dermatology
Background: Botulinum toxin type A (BTX‐A) is the cornerstone for treating dynamic wrinkles; however, it requires reinjection every 3–4 months. Adjunctive topical creams that mimic the effect of BTX‐A and enhance its action may prolong treatment intervals. Objectives: To evaluate the efficacy of a novel formulation containing Subderma‐Complex (arginine, niacinamide, and over‐the‐counter neuromodulating peptides, including: Munapsys, X50 Myocept, Syn‐Ake, and Argireline) in extending the duration of BTX‐A's effect. Methods & Materials: Subjects with moderate‐to‐severe facial wrinkles and a history of regular BTX‐A use applied the Subderma‐Complex serum and creams daily following BTX‐A injection. Reinjection was triggered by the reappearance of the first wrinkle. Outcomes were measured across five visits using the Investigator's Global Assessment, Subject Self‐Assessment, and instrumental analysis (VisioFace Lite). Results: Data from 15 participants were analyzed. The mean reinjection interval increased by 65.2%, from 13.5 ± 1.9 weeks at baseline to 22.3 ± 3.6 weeks following topical treatment ( p < 0.001). Both investigator and patient assessments showed significant reductions in wrinkle severity and improvements in skin quality ( p < 0.001). However, the small sample size and lack of a control group limit the generalizability of the findings. Conclusions: Daily application of a Subderma‐Complex formulation was well‐tolerated and significantly prolonged BTX‐A efficacy, potentially reducing reinjection frequency.